Recently, the 6th issue of the US PharmExec (American Pharmaceutical Manager Magazine) was released, which also brought the latest annual list of the top 50 global pharmaceutical companies. This list is called the "Fortune 500" miniature version of the pharmaceutical industry.
It is reported that the basis for its assessment of whether pharmaceutical companies can be shortlisted is mainly the sales revenue of prescription drugs in fiscal year 2019, so it is possible to understand the overall strength of each company's pharmaceutical business through data. It has a 21-year history since it was first released in 2000 and has a relatively strong credibility.
Due to changes in the market environment last year, as well as many well-known mergers and acquisitions, this year's ranking has undergone some changes.
Roche topped the list for the first time. After China Biopharmaceutical and Hengrui Pharmaceutical entered the list last year, two more Chinese pharmaceutical companies were added this year: Yunnan Baiyao and Shanghai Pharmaceuticals. A total of 4 Chinese pharmaceutical companies entered the list. history record.
Among them, Hengrui Medicine ranked the 43rd on the list with 3.321 billion US dollars of prescription drug sales revenue. It is worth mentioning that in the R&D investment of pharmaceutical companies on the list, Hengrui Pharmaceutical ranked 36th with US$518 million, and ranked first in the list of Chinese pharmaceutical companies.
Judging from the above sales data disclosed by "Pharmaceutical Manager", it is not necessarily accurate, and it does not rule out the fact that the sales of the enterprise's commercial sector are included in the industrial sector.
In this year's list, the top 10 pharmaceutical companies were reshuffled, and two Swiss pharmaceutical companies Roche and Novartis became first and second, respectively.
Roche's prescription drug sales revenue increased by 8.3% in 2019 to reach US$48.247 billion, breaking Pfizer's continuous dominance of the championship in the past four years. This is also the first time Roche has won the global TOP1 pharmaceutical company.
With the continued growth of oncology drugs, Roche relies on the advantages of the tumor pipeline to occupy the position of the first brother of cancer. Against the background of the overall negative growth of Q1 multinational pharmaceutical companies, Roche can still maintain a growth of 3.6%, and the contribution in the field of cancer is indispensable. The sales of the star drug Anvetin accounted for 15% of the total revenue of Roche's pharmaceutical business, which is Roche's number one best-selling drug.
Pfizer's overall ranking fell by two from last year, and its 2019 prescription drug sales fell by 3.6%. Among them, BMS and Takeda Pharmaceuticals both rose 6 places from the 2019 rankings and were shortlisted in the top ten of the list. Pfizer, Johnson & Johnson, Sanofi, AbbVie, GSK fell in ranking.
The big foreign companies we remembered, such as Bayer, GSK and Sanofi, have been hard to find in the top ten clubs, especially Bayer has fallen to eighteenth in the world.
